ArticleJAMA internal medicine2026
Respiratory Outbreak Mitigation With Point-of-Care Testing in Long-Term Care: A Randomized Clinical Trial.
Article in JAMA internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06660433 (imProving Respiratory Outbreak Mitigation Through Point-of-care Testing in Long Term Care), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
imProving Respiratory Outbreak Mitigation Through Point-of-care Testing in Long Term Care (PROMPT-LTC): A Cluster Randomized Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Respiratory infections caused by SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) cause pronounced seasonal morbidity and mortality among residents of nursing homes (NHs). Objective: To assess the effect of an on-site point-of-care respiratory multiplex polymerase chain reaction (POC-RMPCR) instrument on NH outbreaks. Design, Setting, and Participants: This multicenter, open-label cluster randomized trial was conducted from November 12, 2024, to May 2, 2025, in NHs in Toronto, Ontario, Canada. The data analysis was performed from October 7, 2025, until December 31, 2025. Intervention: On-site POC-RMPCR by trained NH staff. Main Outcomes and Measures: The primary outcome was jointly SARS-CoV-2, influenza, and RSV outbreak size and number, and secondary outcomes included the rates of resident emergency department (ED) transfer and death. Results: Among 20 participating NHs with a total of 3963 beds, there was median of 5.5 units, with 30 beds per unit and a crowding index score of 1.42. The joint estimate of outbreak number (51 and 62, respectively) and size for the intervention group was no different from controls, with a rate ratio of 1.12 (95% CI, 0.78 to 1.58). ED transfers for confirmed (-3.5%; 95% CI, -7.2 to -0.2%) and confirmed/suspected infection (-11.0%; 95% CI, -20.6% to -2.0%) were lower among intervention NHs without a difference in death. Viral testing rates (3.69 tests/week vs 1.73 tests/week) and ratio of confirmed to suspect cases (4.2 vs 2.0) were higher in intervention homes along with a shorter time to initiation of antiviral therapy from symptom onset (-2.5 days; 95% CI, -3.1 to -1.9). Conclusions and Relevance: The results of this cluster randomized clinical trial suggests that use of a POC-RMPCR in NHs did not change outbreak number or size but decreased the number of ED transfers in the context of increased viral testing, improved case detection, and faster initiation of antiviral therapy for influenza. Seasonal adoption of POC-RMPCR in NHs would avoid an estimated 4 ED transfers per 100 beds. Trial Registration: ClinicalTrials.gov Identifier: NCT06660433.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.